Investor Presentaiton

ONENESS Ph3 Clinical Trial Results - Satisfactory Safety Profile MRCT (US, China, Taiwan) in 236 subjects Safety Endpoints 62.30% TEAEs 67.50% 11.50% 7.90% 5.70% 4.40% 0% 0.90% Related TEAES Serious TEAE Related Serious TEAEs ■ON101 ■Absorbent Dressing Note: ON101 trade name: Fespixon | 13

View entire presentation